A 2026 Nature Metabolism mouse study from NIH researchers reveals that semaglutide drives weight loss by elevating cAMP in area postrema GLP-1 receptor neurons, with sustained levels determining efficacy. Unlike prior human trials such as the STEP program (Wilding et al., NEJM 2021, n=1961, randomized controlled), this work used fluorescence imaging on living brain slices to map intracellular dynamics rather than behavioral outcomes. By inhibiting PDE4 with roflumilast, researchers prolonged cAMP responses, suggesting a route to reduce dosing frequency or overcome plateaus seen in 60-70% of patients after 68 weeks. This observational preclinical design (small n implied by slice preparations, no human data) lacks the statistical power of large RCTs but identifies a mechanistic gap missed by earlier pharmacokinetic studies focused on peripheral effects. Connections to roflumilast's existing use in COPD hint at rapid repurposing potential, though conflicts of interest in GLP-1 manufacturer funding of follow-on trials warrant scrutiny. Future longitudinal imaging over weeks could clarify tolerance mechanisms absent from current short-term slice data.